Dr. Carl Spana has been the CEO of Palatin Technologies since 2000. He’s a co-founder and has been a driving force in the company for over two decades. His background includes significant experience in the biotechnology sector, having worked at...

Dr. Carl Spana has been the CEO of Palatin Technologies since 2000. He’s a co-founder and has been a driving force in the company for over two decades. His background includes significant experience in the biotechnology sector, having worked at Paramount Capital Investments and Bristol-Myers Squibb prior to starting Palatin. Dr. Spana played a key role in developing the company’s main product, Vyleesi, aimed at treating female sexual dysfunction. In 2022, he secured a new employment agreement which included a base salary of $700,000. Notably, his leadership has been tied to the company achieving major performance milestones, and under his guidance, Palatin has made notable strides in licensing agreements and partnerships, especially with companies like Fosun. With a Ph.D. from Johns Hopkins University, he knows his stuff in molecular biology, which clearly shows in his approach to product development and clinical advancements. He’s not just about running the company; he’s all in when it comes to scientific research and making impactful decisions that shape the future of the company. One interesting point is that he has overseen significant fluctuations in his wealth over the years, particularly during heavy trading periods around the launch of Vyleesi and its FDA approval, indicating strategic involvement in the company's financials.